This announcement replaces the previous announcement issued at 11:10 under the incorrect company
name of Downing Income VCT 4 Plc. The text below reamins unchanged.
The Biotech Growth Trust PLC
1 March 2013
The Biotech Growth Trust PLC
Voting Rights and Capital
In accordance with the Financial Services Authority's Disclosure and
Transparency Rules, The Biotech Growth Trust PLC announces the following:
As at 28 February 2013, The Biotech Growth Trust PLC's capital consists of
ordinary shares of 25p with each ordinary share holding one voting right. The
total number of ordinary shares in issue is 63,356,347. The Company has no
ordinary shares in Treasury.
Therefore, the total number of voting rights in The Biotech Growth Trust PLC is
63,356,347.
The above figure (63,356,347) may be used by shareholders as the denominator
for the calculations by which they will determine if they are required to
notify their interest in The Biotech Growth Trust PLC, or a change to their
interest in The Biotech Growth Trust PLC, under the Financial Services
Authority's Disclosure and Transparency Rules.
- END -
Frostrow Capital LLP
Company Secretary
Tel: 0203 008 4913
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.